About Zymeworks (NYSE:ZYME)
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
SymbolNYSE:ZYMEPrevious Symbol: NASDAQ:ZYME
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$11 million
Price / Sales19.08
Price / CashN/A
Book Value$3.25 per share
Price / Book2.54
Return on Equity-117.85%
Return on Assets-54.48%
Frequently Asked Questions for Zymeworks (NYSE:ZYME)
What is Zymeworks' stock symbol?
Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."
How were Zymeworks' earnings last quarter?
Zymeworks Inc. (NYSE:ZYME) released its quarterly earnings results on Monday, May, 15th. The company reported ($1.13) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million for the quarter. Zymeworks had a negative net margin of 1,387.89% and a negative return on equity of 117.85%. View Zymeworks' Earnings History.
When will Zymeworks make its next earnings announcement?
Where is Zymeworks' stock going? Where will Zymeworks' stock price be in 2017?
6 brokerages have issued 12-month price targets for Zymeworks' shares. Their predictions range from $8.00 to $20.00. On average, they anticipate Zymeworks' stock price to reach $16.00 in the next year. View Analyst Ratings for Zymeworks.
Who are some of Zymeworks' key competitors?
Some companies that are related to Zymeworks include NantKwest (NK), Corbus Pharmaceuticals Holdings (CRBP), Progenics Pharmaceuticals (PGNX), Insys Therapeutics (INSY), CymaBay Therapeutics (CBAY), Seres Therapeutics (MCRB), Stemline Therapeutics (STML), MannKind Corporation (MNKD), Calithera Biosciences (CALA), Mast Therapeutics (SVRA), AVEO Pharmaceuticals (AVEO), ObsEva SA (OBSV), Merus N.V. (MRUS), Biotie Therapies Corp (BITI), Bellicum Pharmaceuticals (BLCM), BioTime (BTX), Ra Pharmctl (RARX) and Geron Corporation (GERN).
Who are Zymeworks' key executives?
Zymeworks' management team includes the folowing people:
- Nick Bedford, Chairman of the Board
- Ali Tehrani Ph.D., President, Chief Executive Officer, Director
- Neil Klompas, Chief Financial Officer
- Surjit Dixit Ph.D., Chief Technology Officer
- Diana Hausman M.D., Chief Medical Officer (Age 52)
When did Zymeworks IPO?
(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.
When did Zymeworks' lock-up period expire?
Zymeworks' lock-up period expired on Wednesday, October 25th. Zymeworks had issued 4,500,000 shares in its public offering on April 28th. The total size of the offering was $58,500,000 based on an initial share price of $13.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the end of the lock-up period.
How do I buy Zymeworks stock?
Shares of Zymeworks can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zymeworks' stock price today?
One share of Zymeworks stock can currently be purchased for approximately $8.27.
How big of a company is Zymeworks?
Zymeworks has a market capitalization of $207.08 million and generates $11 million in revenue each year. Zymeworks employs 136 workers across the globe.
How can I contact Zymeworks?
Zymeworks' mailing address is 1385 West 8th Avenue Suite 540, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]
MarketBeat Community Rating for Zymeworks (ZYME)MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Zymeworks (NYSE:ZYME) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Sell Ratings, 0 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.33)|
|Consensus Price Target: ||$16.00 (93.47% upside)|
Consensus Price Target History for Zymeworks (NYSE:ZYME)
Analysts' Ratings History for Zymeworks (NYSE:ZYME)
(Data available from 11/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/7/2017||Scotiabank||Downgrade||Overweight -> Underweight||High|
|9/7/2017||Barclays PLC||Reiterated Rating||Overweight -> Underweight||$8.00||High|
|5/23/2017||Citigroup Inc.||Initiated Coverage||Buy -> Buy||$18.00||Low|
|5/23/2017||Wells Fargo & Company||Initiated Coverage||Outperform -> Outperform||$20.00||Low|
|5/23/2017||Canaccord Genuity||Initiated Coverage||Buy -> Buy||$18.00||Low|
Earnings History and Estimates Chart for Zymeworks (NYSE:ZYME)
Earnings History by Quarter for Zymeworks (NYSE ZYME)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/14/2018|| || || || || || || || |
Earnings Estimates for Zymeworks (NYSE:ZYME)
Current Year EPS Consensus Estimate: $-3.09 EPS
Next Year EPS Consensus Estimate: $-2.6 EPS
Dividend History for Zymeworks (NYSE:ZYME)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Zymeworks (NYSE ZYME)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Zymeworks (NYSE ZYME)
Financials are not available for this stock.
Zymeworks (NYSE ZYME) Chart for Thursday, November, 23, 2017